Circulating Osteoprotegerin Levels Independently Predict All-cause Mortality in Patients with Chronic Kidney Disease: a Meta-analysis

Huang, Qing-xiu; Li, Jianbo; Huang, Xiaowen; Jiang, Lanping; Huang, Lin; An, Hai-wen; Yang, Wenqin; Pang, Jie; Liu, Yanlin; Huang, Fengxian

doi:10.7150/ijms.34274

Cited by 6 publications

(5 citation statements)

References 42 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study ,OPG levels increase in CKD Patients with highly significant differences (P≤0.01). OPG is also implicated in metabolic bone disease and may patients control have a role in CKD prognosis (14). OPG levels are higher in patients with chronic renal disease (15).…”

Section: Discussionmentioning

confidence: 99%

Assessment of osteoprotegerin as bone marker in chronic kidney disease patients

Khalef

Joda

Al-Sultani

2022

ijhs

View full text Add to dashboard Cite

Chronic kidney disease is a chronic impairment in the structure or function of the kidney. (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg per 24 hours) for more than 3 months.Renal osteodystrophy is a change in bone morphology in CKD patients, and it is one marker of the skeletal component of the systemic condition of chronic kidney disease mineral bone disease (CKD-MBD) that can be quantified using histomorphometry on bone biopsies chronic kidney disease mineral bone disease (CKD-MBD) defines a complex syndrome of renal osteodystrophy, mineral disorders and cardiovascular disease in patients with chronic kidney disease. The study was a case –control design which conducted in Dialysis Unit in AL-Mahmoodia General Hospital and ALyarmook Teaching Hospital in Baghdad. This study was carried out in private laboratories between September 2021to march 2022. In this investigation,the total subjects were 90, the patient group was Consist of 45 Hemodialysis (HD) (CKD) ( 18 males and 27 females).

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of osteoprotegerin as bone marker in chronic kidney disease patients

Khalef

Joda

Al-Sultani

2022

ijhs

View full text Add to dashboard Cite

show abstract

“…The OPG level signals an independent risk of coronary calcification 23 and of all-cause mortality. 24 Genetically, OPG/RANKL polymorphism in hemodialysis and its association with aortic calcification have been proposed. 25 High-level serum RANKL expression stimulated by PTH is also inferred to occur in patients undergoing hemodialysis.…”

Section: Discussionmentioning

confidence: 99%

Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis

Suzuki

Hanafusa

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

Introduction Aortic arch calcification (AoAC) is related closely to mortality risk in patients undergoing maintenance dialysis. Recent experimentally obtained data suggest that osteoprotegerin/receptor activator for nuclear factor κB ligand signal transmission plays a role in de novo chondrogenic transition of vascular cells leading to calcification that is unrelated to bone metabolism. This study investigated the long-term effects of denosumab, an osteoprotegerin mimic peptide, on AoAC. Methods This study examined 58 patients with an 8 year vintage of dialysis at 1 center for observational study during 2009 to 2020. Denosumab was administered to 28 patients every 6 months. Blood chemical data were used. AoAC proportions were measured using a simple but computed tomography–equivalent computer-based chest X-ray analysis (calcified pieces of areas around the aorta). Results Blood chemical data of the control and denosumab groups that did not differ at the start showed differences of mineral metabolism after 30 months of observation. Remarkably, the AoAC proportion increased from 29.4% to 46.25% in the control group but decreased significantly from 25.0% to 20.0% ( P < 0.01) in the denosumab group. Denosumab effects on decalcification were not observed 12 months after initiation. Conclusion We conclude that long-term use of denosumab is effective to reverse or treat AoAC in patients undergoing hemodialysis.

show abstract

“…Despite the debate on the role of circulating OPG in atherosclerotic disease [ 31 ], as an experimental study reported that exogenous OPG treatment lead to endothelial and vascular smooth cell dysfunction by promoting the production of reactive oxygen species, which may underlie vascular injurious effects in conditions such as hypertension [ 32 ], the phenotype of OPG-knockout mice ultimately indicates circulating OPG as a biomarker, rather than a mediator, of atherosclerosis, as OPG-deficient mice develop early onset arterial calcification [ 33 ]. In this context, the association of high serum OPG level with coronary artery calcification [ 15 , 16 ], and cardiovascular [ 17 , 18 ] and all-cause mortality [ 19 , 20 ] in patients with CKD has been suggested. The association between serum OPG level with long-term visit-to-visit BPV presented in this study highlights a novel role of circulating OPG as a biomarker that predict a surrogate of CV events.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies demonstrated that high serum OPG level is associated with the presence [ 15 ] and severity [ 16 ] of coronary artery calcification in patients with CKD. In this regard, elevated circulating OPG level has been proposed as a predictor of cardiovascular [ 17 , 18 ] and all-cause [ 19 , 20 ] mortality in patients with CKD. Serum OPG level is positively associated with peripheral artery disease, arterial stiffness, and arterial calcification in patients with end-stage renal disease [ 21 , 22 , 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Association of Circulating Osteoprotegerin Level with Blood Pressure Variability in Patients with Chronic Kidney Disease

Suh

Choi

et al. 2021

JCM

View full text Add to dashboard Cite

Circulating osteoprotegerin (OPG) is a biomarker for cardiovascular complications that are closely related to chronic kidney disease (CKD). To investigate the association between circulating OPG level with long-term visit-to-visit blood pressure variability (BPV) in patients with pre-dialysis CKD, a total of 1855 subjects with CKD from stage 1 to pre-dialysis stage 5 from a prospective cohort were analyzed. Long-term visit-to-visit BPV was determined by average real variability (ARV), standard deviation (SD), and coefficient of variation (CoV) of systolic and diastolic blood pressure (SBP and DBP). ARV of SBP (Adjusted β coefficient 0.143, 95% confidence interval 0.021 to 0.264) was significantly associated with serum OPG level. Although SD and CoV of SBP were not significantly associated with serum OPG level in multivariate linear regression analyses, restricted cubic spline visualized the linear correlation of serum OPG level with all of ARV, SD, and CoV. The association between serum OPG level and DBP variability was not significant. Subgroup analyses revealed that the association of serum OPG with BPV is more prominent in the subjects with Charlson comorbidity index ≤3 and in the subjects without history of diabetes mellitus. In conclusion, circulating OPG level is potentially associated with long-term visit-to-visit BPV in patients with pre-dialysis CKD.

show abstract

Circulating Osteoprotegerin Levels Independently Predict All-cause Mortality in Patients with Chronic Kidney Disease: a Meta-analysis

Cited by 6 publications

References 42 publications

Assessment of osteoprotegerin as bone marker in chronic kidney disease patients

Assessment of osteoprotegerin as bone marker in chronic kidney disease patients

Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis

Association of Circulating Osteoprotegerin Level with Blood Pressure Variability in Patients with Chronic Kidney Disease

Contact Info

Product

Resources

About